QI
TCRT icon

QS Investors’s Alaunos Therapeutics TCRT Stock Holding History

QS Investors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Hold
0
– -$1K – 2061
2016
Q1 		– Hold
0
– – – 1768
2015
Q3 		– Sell
-10
Closed -$18K – 1468
2015
Q2 		$18K Hold
10
– – ﹤0.01% 1351
2015
Q1 		$16K Hold
10
– – ﹤0.01% 1339
2014
Q4 		$8K Buy
+10
New +$5.31K ﹤0.01% 1351

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

QS Investors's TCRT Position: Q2 2016 in Review

QS Investors held its Alaunos Therapeutics (TCRT) position steady in Q2 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2061.

QS Investors first reported a position in TCRT in Q4 2014 and has held it in 3 quarters since. The position peaked at $18K in Q2 2015. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • QS Investors held 0 shares of Alaunos Therapeutics worth $0 as of Q2 2016.
  • QS Investors left its Alaunos Therapeutics share count unchanged in Q2 2016.
  • Alaunos Therapeutics made up ﹤0.01% of QS Investors's portfolio in Q2 2016, its #2061 holding.
  • QS Investors first reported a position in Alaunos Therapeutics in Q4 2014 and has held it in 3 quarters since.
  • QS Investors's Alaunos Therapeutics position peaked at $18K in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on QS Investors's 13F filing for Q2 2016, filed 15 Aug 2016.